SPOTLIGHT: Trial failure hits Evolutec

The Times is reporting that Evolutec is being put up on the sales block following the failure of its lead candidate in a mid-stage trial. Researchers for the company said that rEV131 had failed to reduce inflammation in patients following cataract surgery. The company has a market capitalization of 4 million pounds sterling. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.